Tardive dyskinesia

Motor system impairments, cognition and everyday functioning

Martin Strassnig, Amie Rosenfeld, Philip D Harvey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.

Original languageEnglish (US)
Pages (from-to)370-377
Number of pages8
JournalCNS Spectrums
Volume23
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

Cognition
Antipsychotic Agents
Attention Deficit Disorder with Hyperactivity
Activities of Daily Living
Autistic Disorder
Tardive Dyskinesia
Bipolar Disorder
Prescriptions
Chronic Disease
Depression
Therapeutics
Population

Keywords

  • cognition
  • disability
  • Key wordsTardive dyskinesia
  • motor function
  • physical performance

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Tardive dyskinesia : Motor system impairments, cognition and everyday functioning. / Strassnig, Martin; Rosenfeld, Amie; Harvey, Philip D.

In: CNS Spectrums, Vol. 23, No. 6, 01.12.2018, p. 370-377.

Research output: Contribution to journalArticle

Strassnig, Martin ; Rosenfeld, Amie ; Harvey, Philip D. / Tardive dyskinesia : Motor system impairments, cognition and everyday functioning. In: CNS Spectrums. 2018 ; Vol. 23, No. 6. pp. 370-377.
@article{e75dbe3f8781480c9989fee0a71d96f0,
title = "Tardive dyskinesia: Motor system impairments, cognition and everyday functioning",
abstract = "The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.",
keywords = "cognition, disability, Key wordsTardive dyskinesia, motor function, physical performance",
author = "Martin Strassnig and Amie Rosenfeld and Harvey, {Philip D}",
year = "2018",
month = "12",
day = "1",
doi = "10.1017/S1092852917000542",
language = "English (US)",
volume = "23",
pages = "370--377",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "6",

}

TY - JOUR

T1 - Tardive dyskinesia

T2 - Motor system impairments, cognition and everyday functioning

AU - Strassnig, Martin

AU - Rosenfeld, Amie

AU - Harvey, Philip D

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.

AB - The recent approval of treatments for tardive dyskinesia (TD) has rekindled interest in this chronic and previously recalcitrant condition. A large proportion of patients with chronic mental illness suffer from various degrees of TD. Even the newer antipsychotics constitute a liability for TD, and their liberal prescription might lead to emergence of new TD in patient populations previously less exposed to antipsychotics, such as those with depression, bipolar disorder, autism, or even attention deficit hyperactivity disorder. The association of TD with activity limitations remains poorly understood. We review potential new avenues of assessing the functional sequelae of TD, such as the performance of instrumental activities of daily living, residential status, and employment outcomes. We identify several mediating aspects, including physical performance measures and cognition, that may represent links between TD and everyday performance, as well as potential treatment targets.

KW - cognition

KW - disability

KW - Key wordsTardive dyskinesia

KW - motor function

KW - physical performance

UR - http://www.scopus.com/inward/record.url?scp=85059247389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059247389&partnerID=8YFLogxK

U2 - 10.1017/S1092852917000542

DO - 10.1017/S1092852917000542

M3 - Article

VL - 23

SP - 370

EP - 377

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 6

ER -